At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 58 target
Drug / intervention
famitinib po +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating famitinib po and HS-10296 po for EGFR-mutant Non-Small Cell Lung Cancer. Targeting 58 participants across 1 site.
Detailed Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEGFR-mutant Non-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionDec 2022
TodayJul 2026
First PostedApr 5, 2019
Enrollment StartApr 25, 2019
Primary CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 7.2 years ago
Interventions
famitinib podrug
Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
HS-10296 podrug
Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.